Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 43 Presentations at the 74th American Diabetes Association Scientific Sessions
More than 40 posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer Ingelheim (BI) and Eli Lilly and Company diabetes portfolio at the 74th American Diabetes Association (ADA) Scientific Sessions in San Francisco, June 13–17. The commitment of the BI-Lilly Diabetes alliance to the care of adults with diabetes is exemplified by a focus on compounds representing several of the largest diabetes treatment classes.
LY2963016, Investigational New Insulin Glargine Product Data
A total of six clinical abstracts for the investigational basal (long-acting) insulin LY2963016, new insulin glargine product, will be presented. LY2963016 is a new insulin glargine product being developed for the treatment of patients with type 1 and type 2 diabetes.
Details of all clinical presentations and posters are as follows:
Saturday, 14 June, 8:00 - 10:00 a.m. PT, Oral Presentation - Basal Insulin Therapy
• Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T2D: the ELEMENT 2 Study (Presenting Author: J. Rosenstock) [Oral No. 64-OR]
• Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1D: the ELEMENT 1 Study (Presenting Author: T. Blevins) [Oral No. 69-OR]
• Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1D or T2D (Presenting Author: M. Deeg) [Oral No. 70-OR]
Saturday, 14 June, 11:30 a.m. - 1:30 p.m. PT, General Poster Session
• Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of LY2963016 Insulin Glargine and EU- and US-approved Versions of Lantus Insulin Glargine in Healthy Subjects (Presenting Author: H. Linnebjerg) [Poster No. 889-P]
• Comparative Pharmacokinetics and Pharmacodynamics of Two Insulin Glargine Products, LY2963016 and Lantus, in Healthy Subjects at Two Dose Levels (Presenting Author: X. Zhang) [Poster No. 890-P]
• Duration of Action of 2 Insulin Glargine Products, LY2963016 and Lantus, in Subjects with Type 1 Diabetes Mellitus (T1DM) (Presenting Author: T. Heise) [Poster No. 891-P]
Posters 889-P, 890-P and 891-P will also be featured in a guided audio poster tour on Monday 16 June, 1:00 - 1:50 p.m. PT, titled "Pharmacokinetic/Pharmacodynamic Insulin Studies."
Posters 889-P, 890-P and 891-P will also be featured in a guided audio poster tour on Monday 16 June, 1:00 - 1:50 p.m. PT, titled "Pharmacokinetic/Pharmacodynamic Insulin Studies."
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance